BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GTx-758: Phase II data

An open-label Phase II trial in 60 healthy male volunteers showed that 1,000 and 1,500 mg/day oral GTx-758 suppressed serum total testosterone to castrate levels of <50 ng/dL within 3 weeks, while the 600 mg dose did...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >